PARP Inhibitors in the Management of Ovarian Cancer

Publication Date: September 23, 2022

Key Points

Key Points

  • These recommendations pertain only to patients with epithelial ovarian, tubal, or primary peritoneal cancer who have not previously received a poly(ADP-ribose) polymerase inhibitors (PARPi).
  • The recommendations are based on clinical trial results and FDA approvals and do not necessarily capture regulatory approvals in other jurisdictions.

Treatment

...eatment

...peating PARPi...

...1.0Repeating PARPi therapy in the treatmen...


...gnosed Ovarian Cancer...

...ation 2.0PARPi are NOT recommended...

...– Recommendation 2.1Patients with newl...

...mmendation 2.2The addition of olaparib to b...

...ndation 2.3Inclusion of the PARPi, veliparib, wit...


...n Cancer - Second-line or Greater Maintena...

Rapid Update – Recommendation 3...

...py maintenance (second-line or more) may b...

...treatment with niraparib for patients wit...

...pid Update – Recommendation 3.1/3.2PA...

...pdate – Recommendation 3.3PARPi monotherapy...


PARPi in Combinat...

...4.0PARPi are NOT recommended for use...


...ent of Adverse Events...

...dation 5.0 Anemia...

...s requiring a blood transfusion for...

...tients with progressive anemia may be...

...commendation 5.1 Neutro...

...h factor is NOT indicated for use in p...

...penia (grade 4 lasting at least 5–7 d...

...mmendation 5.2 Platelets:

a. Thrombocytopenia is most common with niraparib...

...nue PARPi for persistent thrombocytopenia or sign...

...dation 5.3 Persistent cytopenia:Evaluation for tre...

...ommendation 5.4 Nausea...

...Many patients will have tachyphylaxis of nausea sy...

b. Persistent nausea requiring daily...


...le 1. PARP Inhibitors in the Management of O...


...PARPi Use Opportunities in PARPi-Naïve Women N...